Host Genetic Factors in Susceptibility to Herpes Simplex Type 1 Virus Infection: Contribution of Polymorphic Genes at the Interface of Innate and Adaptive Immunity

Manuela Moraru, Elisa Cisneros, Natalia Gómez-Lozano, Rosario de Pablo, Francisca Portero, María Cañizares, Mercedes Vaquero, Gastón Roustán, Isabel Millán, Miguel López-Botet and Carlos Vilches

*J Immunol* published online 4 April 2012
http://www.jimmunol.org/content/early/2012/04/04/jimmunol.1103434

**Supplementary Material**
http://www.jimmunol.org/content/suppl/2012/04/04/jimmunol.1103434.DC1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Host Genetic Factors in Susceptibility to Herpes Simplex Type 1 Virus Infection: Contribution of Polymorphic Genes at the Interface of Innate and Adaptive Immunity

Manuela Moraru,* Elisa Cisneros,* Natalia Gómez-Lozano,* Rosario de Pablo,* Francisca Portero,‡ María Cañizares,† Mercedes Vaquero,§ Gastón Roustán,§ Isabel Millán,¶ Miguel López-Botet,‖ and Carlos Vilches*

HSV-1 establishes life-long latency that can result in clinical relapses or in asymptomatic virus shedding. Although virtually all adults have been exposed to HSV-1, the clinical course varies remarkably. Genetic host variability could be related to this clinical diversity. In this study, we analyzed the contribution of gene families in chromosomes 1, 6, 12, and 19, which encode key regulators of the innate and adaptive immunity, in a cohort of 302 individuals. Class I and class II alleles of the HLA system, the copy-number variation of NK cell receptor genes (KIR and NKG2C), the combinations of killer cell Ig-like receptor and their HLA ligands, and CD16A and CD32A allotypes of variable affinity for IgG subclasses were all studied. Although no major susceptibility locus for HSV-1 was identified, our results show that the risk of suffering clinical HSV-1 infection is modified by MHC class I allotypes (B*18, C*15, and the group of alleles encoding A19), the high-affinity receptor/ligand pair KIR2DL2/HLA-C1, and the CD16A-158VF dimorphism. Conversely, HLA class II and CD32A polymorphisms and NKG2C deletion did not seem to influence the clinical course of herpetic infection. Collectively, these findings support an important role in host defense against herpetic infection for several polymorphic genes implicated in adaptive immunity and in surveillance of its subversion. They confirm the crucial role of cytotoxic cells (CTL and NK) and the contribution of genetic diversity to the clinical course of HSV-1 infection.  

The Journal of Immunology, 2012, 188: 000–000.

Most adults have suffered HSV-1 infection. The virus migrates from mucosae or skin to sensory ganglia, where it establishes life-long latent infection. Virus propagation is controlled by innate and adaptive immunity, and the course of the infection depends upon the host immune system capacity to control both the primary infection and the reactivations. HSV-1 replication in keratinocytes and mucosal cells triggers a strong cytokine response. IFN-α produced by dendritic cells (DC) and IFN-γ secreted by NK and, later, CD4+ T cells represent a first line of direct antiviral defense (1). IFNs also promote subsequent adaptive immune response by enhancing Ag presentation (2).

CD8+ CTLs eliminate infected cells presenting HSV-1 peptides on HLA class I molecules, and they are responsible for immunosurveillance during viral latency (3, 4). In addition, DC present viral Ags bound to HLA class II molecules to CD4+ T lymphocytes, which enhance differentiation and establishment of functional memory CTLs (1) and Ab-mediated control of HSV-1.

Key components of innate cellular immunity to viruses are NK cells, which kill infected cells without presensitization, secrete antiviral cytokines, and favor DC maturation. Their behavior depends on the balance of signals transduced by activating and inhibitory receptors that survey altered molecular patterns on infected cells (5, 6). Their best-known trigger is HLA class I downregulation, monitored by several families of NK cell receptors (7). Furthermore, NK lymphocytes exert Ab-dependent cellular cytotoxicity (ADCC) against Ab-coated infected cells by means of FcγR.

HSV-1, like other herpesviruses, has developed mechanisms to circumvent the host immune response. Infected cell protein (ICP) 47 binds the transporter for antigenic peptides (TAP), thus hampering HLA class I-mediated Ag presentation by infected cells to T lymphocytes (8). Furthermore, HSV-1 glycoproteins gE and gI form an FcR on both the viral envelope and the infected cell membrane, where it can compete, directly and through Ab bipolar bridging, with host FcγR, protecting the infected cells from complement- and cell-mediated lysis (9).

Although virtually all adults have been exposed to HSV-1, the clinical course of the infection varies remarkably, ranging from asymptomatic virus shedding to frequent inflammatory herpetic lesions and potentially life-threatening episodes of herpetic encephalitis. Clinical variability is attributable to the virus itself (e.g., HSV-1 strains, amount of inoculum), the environment (e.g., exposure to UV light and other triggers), and variations in the host immune response. Herpetic encephalitis and isolated cases of fatal HSV-1 infection have been associated with rare mutations in innate...
immunity-related genes (10–14). A recent linkage analysis detected in chromosome 21 a 2.5-megabase susceptibility region for herpes simplex labialis (15). However, predictive genetic markers that explain the pathogenesis of the common outcomes of HSV-1 infection are yet to be identified.

An attractive candidate to influence the course of HSV-1 infection is the enormous diversity of the HLA complex in chromosome 6, credited with a large proportion of the variability of immune responses, because it could modify the efficacy of HSV-1-antigen presentation. Several groups have analyzed the contribution of HLA allootypes to the clinical diversity of HSV-1 infection, but many results did not replicate in different populations (16–27).

Killer cell Ig-like receptors (KIR), encoded by a highly polymorphic gene complex in chromosome 19, represent another series of candidates to influence the HSV-1 infection outcome because they help NK cells fight viruses that tamper with HLA expression (28). The most conspicuous aspect of KIR gene diversity is copy-number variation (CNV); most humans are natural knockouts for multiple KIR genes, with only the genes at the centromeric and the telomeric ends of the KIR complex being conserved. We have previously identified an association between symptomatic HSV-1 infection and presence in the genome of the linked genes KIR2DL2 and KIR2DS2 (29).

Also used by NK cells to sense HLA expression are CD94/NKG2 heterodimers encoded in the NK complex of chromosome 12, which comprise both activating and inhibitory receptors for HLA-E (30, 31). In sharp contrast with KIR, the CD94 and most NKG2 genes are well conserved (32), one remarkable exception being complete deletion of NKG2C (KLRC2) in some individuals (33, 34). The consequence of NKG2C deletion for immunity and health is unknown, but marked expansion of NKG2C-positive NK and T lymphocytes in response to CMV infection (35, 36) suggests a role for NKG2C in defense against herpesviruses.

Finally, the genes in chromosome 1 coding for the FcγR CD16A (FCGR3A) and CD32A (FCGR2A) display allelic polymorphisms that modulate their affinity for IgG (37). High-affinity FcγRs could enhance ADCC and compete with the decay FcγR formed by HSV-1 gE/gI, thus improving the efficacy of humoral response against HSV-1.

Whether and how virus evasion mechanisms may be counteracted by host defense and to which extent immunogenetic variability contributes to the clinical outcomes of herpetic infection is yet to be established. In this study, we have analyzed the contribution of the genetic diversity of the HLA system and the KIR, NKG2C, CD16A, and CD32A receptors to the clinical variability of HSV-1 infection.

Materials and Methods

Donor and patient samples

Three hundred two individuals, the vast majority of whom were of Spanish origin, were interviewed about the presence and frequency of previous or actual clinical evidence of HSV-1 infection. Individuals reporting any diseases or therapies that might debilitate an immune response or symptoms doubtfully attributable to HSV-1 infection were excluded from this study; also excluded were donors seropositive for HSV-2. The total group included 253 voluntary adults and 49 patients who sought medical assistance for herpetic lesions. From the total population, 131 individuals had been in-
included in a previous study in which we analyzed the influence of the KIR diversity on the clinical course of the HSV-1 infection (29). In this study, we have replicated that study on KIR diversity in a 171-individual population with similar characteristics. Moreover, we have analyzed, in the whole sample of 302 individuals, the relationship between the outcome of HSV-1 infection and HLA, NKG2C, and FCGR polymorphisms.

Venous blood samples collected from all donors were used to isolate serum and genomic DNA. Serum IgG/IgM Abs against HSV-1+2 common Ags and HSV-2 gG2 Ag were detected by ELISA and evaluated as recommended by the manufacturer (Vircell, Granada, Spain).

Based on reported episodes of symptomatic herpes infection (most often, cold sores) after a standardized questionnaire, the total sample was subdivided into two categories: asymptomatic and symptomatic individuals. When considering the serologic findings and the frequency of HSV-1 reactivations, each of the previous groups was further separated, resulting in a total of four subcategories: 1) asymptomatic seronegatives; 2) asymptomatic seropositives; 3) donors with sporadic clinical reactivations (less than two reactivations yearly in the maximum activity period); and 4) patients with recurrent reactivations (two or more per year).

HLA, KIR, NKG2C, FCGR2A, and FCGR3A genotyping

HLA class I (HLA-A, -B, and -C) and class II (HLA-DRB1, -DRB3, -DRB4, and -DRB5) typing was carried out using a reverse line PCR sequence-specific oligonucleotide test (Invitrogen-Dynal ReLi-SSO, Wirral, U.K.). KIR genotyping was performed using a PCR with a sequence-specific primer method designed by our group (38). On the basis of gene content, two categories of KIR haplotypes have been established, designated A and B. These share some KIR genes and pseudogenes (3DL2, 3DL3, and, in most cases, 2DL4 and 3DP1), whereas they diverge in the remaining KIR genes. Besides the shared framework genes, the A haplo-
type carries: genes coding for the inhibitory KIR 2DL1, 2DL3, and 3DL1; for KIR2DS4, as the only activator; and one pseudogene, KIR2DP1. By contrast, the hallmark of B haplotypes is the replacement of one or more of the latter six genes by variable combinations of KIR not seen in the A-haplotype: 2DL2, 2DL5, and genes encoding activating KIR different from A*68. According to this, we assigned an AA genotype to individuals having all and only KIR genes corresponding to an A-haplotype; a BX genotype, when all the previous genes, as well as any of those characteristic of B-haplotypes, were present; and a BB-genotype when any gene of the A-haplotype was missing and one or more of those included in a B-haplotype were present. The assignment of a BX genotype was based exclusively on gene content; such designation was used instead of AB so as not to imply that the genes that form an A-haplotype were inherited in cis.

Joint KIR/ligand analysis considered the interactions of KIR 2DL1 and 2DS1 with HLA-C alleles with lysine at position 80 of the α-chain (HLA-C2 epitope); KIR 2DL2 and 2DL3 with HLA-C alleles bearing asparagine at the same position (80) (HLA-C1 epitope); KIR3DL1 with HLA-B and HLA-A alleles having the Bw4 epitope (excluding A*25); KIR3DL2 with HLA-A*03 and A*11 alleles; the recently demonstrated interaction of full-length KIR2DS4 with HLA-A*11 and subsets of HLA-C alleles (C*01, *02, *04, *05, *14, and *1601) (39); and KIR3DS1 with Bw4, because of its apparent genetic interaction in viral infection (40).

Homozygous and heterozygous deletion of the NKG2C gene were assessed by a PCR method based on the approach used by Miyashita et al. (34), with modifications (M. Moraru, M. Canizares, A. Muntasell, R. de Pablo, M. López-Botet, C. Vilches, submitted for publication, details available upon request).

Functional polymorphisms of FCGR2A and FCGR3A were determined using a PCR with confronting two-pair primers, as described (41).

MHC epitope prediction

To predict HSV-1 peptide binding to specific HLA molecules, we have used the NetCTLpan tool (http://www.cbs.dtu.dk/services/NetCTLpan/), which integrates information on proteasomal cleavage, TAP transport efficiency, and MHC binding affinity (42).

Statistical analysis

Gene frequencies were estimated by direct counting, and they were analyzed by univariate analysis of their distribution in symptomatic and asymptomatic individuals using a PCR method based on the approach used by Miyashita et al. (34), with modifications (M. Moraru, M. Canizares, A. Muntasell, R. de Pablo, M. López-Botet, C. Vilches, submitted for publication, details available upon request).

Functional polymorphisms of FCGR2A and FCGR3A were determined using a PCR with confronting two-pair primers, as described (41).

MHC epitope prediction

To predict HSV-1 peptide binding to specific HLA molecules, we have used the NetCTLpan tool (http://www.cbs.dtu.dk/services/NetCTLpan/), which integrates information on proteasomal cleavage, TAP transport efficiency, and MHC binding affinity (42).
was also included because of its previous identification as a protective factor, as was the KIR2DL1/C2 combination, for its apparently cumulative effect on the risk conferred by KIR2DL2/C1.

Results
Cohort demographic characteristics
We studied 302 adult individuals, of whom 164 had symptomatic HSV-1 infection and 138 were asymptomatic. The mean age of the whole sample was 40.3 ± 12.7 y, the symptomatic and the asymptomatic groups having similar ages (Supplemental Table I, Table I). Sixty-five percent of the donors were women, who predominated in the group developing clinical herpetic infection (p = 0.002) and, in particular, among individuals with two or more reactivations per year (p = 0.0001, when compared with the rest of the population). This finding is in line with previous observations on the gender distribution of patients with recurrent HSV-1 infection (44).

Influence of HLA diversity on the outcome of HSV-1 infection
To explore whether and how the extreme HLA polymorphism conditions the clinical efficacy of adaptive responses against HSV-1, we analyzed the HLA alleles of all individuals included in this study. HLA class II allotypes had remarkably similar distributions in symptomatic and asymptomatic donors (Fig. 1, Supplemental Table II). In contrast, several HLA class I alleles displayed less even distributions in the two subgroups (Fig. 1, Supplemental Table II), although only two of the apparent differences between symptomatics and asymptomatics reached statistical significance. In particular, HLA-B*18 was overrepresented in the asymptomatic group (p = 0.003; odds ratio [OR], 0.34), and HLA-B*35, reported to associate negatively with herpes in Italians (19), showed a trend in the same direction (one-tailed p = 0.075; OR, 0.60). On the contrary, HLA-C*15 was more frequently encountered among symptomatic individuals (p = 0.013; OR, 4.53).

The most common HLA class I allotype, A*02, was slightly less represented in asymptomatic than in symptomatic donors (Fig. 1). Stratification of asymptomatic donors for presence or absence of HSV-1–specific Abs showed that HLA-A*02 was underrepresented solely in seronegative individuals (37.3%), whereas seropositive asymptomatic and symptomatic donors all had A*02 frequencies (52.1 and 49.4%, respectively) similar to those reported in Spanish individuals (45, 46), but that difference was only close to significance (p = 0.072 for the comparison between HSV-1 seronegatives and all other donors). Comparison of the HLA allele distribution in the four subgroups of patients showed no other significant differences (Supplemental Table II).

HSV-1 peptide binding profiles of HLA class I molecules
To identify functional differences between HLA-B*18, B*35 and C*15 that could explain their divergent influence on risk of clinical HSV-1 infection, we used a tool for peptide-binding prediction to MHC molecules (42). We focused on differences in presentation of peptides derived from immediate early HSV-1 genes, because these are transcribed upon viral entry without prior viral protein synthesis, and they encode Ags expressed in latency (47). The products of all common B*18 and B*35 alleles of white populations (B*18:01, B*35:01–B*35:03, and B*35:08) were predicted to present a unique 9-mer peptide (EPAPDVWVF) from ICP0; in contrast, no ICP0-derived peptides were potential ligands for HLA-C*15 (alleles C*15:02 and C*15:05). The ICP27 gene encodes several potential nonamer ligands for HLA-B*18 and C*15, but none for B*35. Peptides from all other immediate early gene products were similarly presented by all three MHC molecules.

Influence of KIR gene diversity on the clinical course of HSV-1 infection
Previous analysis of KIR-gene CNV in 131 out of the 302 donors studied in this article showed that resistance to clinical HSV-1

<table>
<thead>
<tr>
<th>Category</th>
<th>Women [n (%)]</th>
<th>Men [n (%)]</th>
<th>Mean Age (y) (± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatics</td>
<td>77 (55.8)</td>
<td>61 (44.2)</td>
<td>38.9 (± 11.0)</td>
</tr>
<tr>
<td>Symptomatics</td>
<td>120 (73.2)</td>
<td>44 (26.9)</td>
<td>41.6 (± 13.9)</td>
</tr>
<tr>
<td>Total (n = 302)</td>
<td>197 (65.2)</td>
<td>105 (34.8)</td>
<td>40.3 (± 12.7)</td>
</tr>
</tbody>
</table>

FIGURE 1. Phenotypic frequencies of common HLA alleles in symptomatic and asymptomatic individuals. Only the alleles with a frequency >5% in at least one subgroup are represented in this figure; the exact frequencies of all studied alleles are shown in Supplemental Table II. *p < 0.05, **p < 0.01.
infection associates with the absence of KIR2DL2 and KIR2DS2 from the genome (29). In this study, we replicated that study in another group of 171 individuals of similar characteristics and origins. We observed small deviations in the same direction (e.g., 59.8% of symptomatics, versus only 55.7% of asymptomatics, had a KIR2DL2 gene) (Fig. 2, Supplemental Table III), but they were not statistically significant. Yet, in the total sample of 302 individuals, the increase of KIR2DL2 and KIR2DS2 in clinical HSV-1 infection retained statistical significance (p = 0.011, OR = 1.83; and p = 0.027, OR = 1.69, respectively). As was the case in our first study, all other KIR genes were distributed similarly in the symptomatic and asymptomatic subgroups of the replication sample (Fig. 2A), as well as in patients with recurrent and sporadic symptoms (data not shown).

On the basis of gene content, two categories of KIR haplotypes have been established, designated A and B, which combine into an array of diverse AA, BX, and BB genotypes, for which distribution was compared in donors with or without HSV-1 symptoms. Consistent with the observed differences in the frequencies of KIR 2DL2 and 2DS2, genes present only in B-haplotypes, reciprocal deviations in the frequencies of the AA and BB genotypes were seen (Fig. 2B, Supplemental Table IV), but those deviations were only close to statistical significance (p < 0.1).

The number of activating KIR encoded by different genotypes ranges from six to none (when KIR2DS4 is represented in both chromosomes of an AA genotype by null alleles, dominant in white populations), and this variation might modulate the activation threshold of NK cells. However, search for possible association between the number of genes for activating KIR and the clinical course of HSV-1 infection showed no significant differences between asymptomatic donors and patients with either sporadic or recurrent symptoms (Fig. 2C and data not shown).

KIR/HLA ligand pairs of higher avidity increase the risk of clinical HSV-1 infection

We refined the study of KIR genotypes by considering the simultaneous presence of a receptor and its known or presumed ligand in the same individual. The receptor/ligand pair 2DL2/HLA-C1 was more commonly encoded in symptomatic than in asymptomatic donors (p = 0.011, OR = 1.87) (Fig. 3, Supplemental Table IV). This had been originally observed in our first study (29) and was reproduced with marginal significance in the replication cohorts (58.7 versus 45.6%; OR = 1.70; single-tailed p = 0.059). Furthermore, when the HSV-1 reactivation rate was considered, a highly significant gradient in the 2DL2/C1 distribution was observed: its frequency was highest in patients with frequently recurrent HSV-1 reactivations and lowest in donors without symptoms (p = 0.005; Table II).

The proportion of individuals encoding both high-affinity receptor/ligand pairs 2DL2/HLA-C1 and 2DL1/HLA-C2 is also increased among symptomatically infected individuals (p = 0.005; OR = 2.13), in whom lack of both receptor/ligand pairs was rarer than in asymptomatic individuals (p = 0.032, OR = 0.51, Fig. 3). As a consequence, presence of both, either, or none of the two pairs caused a linear increase in the risk of having HSV-1 symptoms (Mantel–Haenszel χ2; p = 0.002) (Supplemental Table IV). Coincident increase of both receptors and their respective ligands in the same group of patients is noticeable because KIR2DL2 is often inherited in haplotypes that lack a KIR2DL1 gene; furthermore, C1 and C2 are mutually exclusive allelotypes of the same locus. These findings prompted an analysis of C1-C2 genotype distribution in symptomatic patients, which did not fit the Hardy–Weinberg equilibrium, and this was due to predominance of heterozygosity: 29% C1C1, 58% C1C2, and 13% C2C2 (p = 0.017). This distribution differed significantly from that of asymptomatic controls (38% C1C1, 46% C1C2, 17% C2C2; p = 0.011), in whom these alleles were in Hardy–Weinberg equilibrium. The rest of inhibitory or activating KIR/ligand pairs did not show significant differences in their distribution (Fig. 3 and data not shown).

NKG2C gene deletion does not influence the clinical course of HSV-1 infection

The gene encoding the HLA-E receptor NKG2C, which marks HSV-1 infection showed no significant differences between asymptomatic donors and patients with either sporadic or recurrent symptoms (Fig. 2C and data not shown).
CMV, is deleted in some Asian and European individuals (33, 34); therefore, we searched for possible relation between CMV, is deleted in some Asian and European individuals (33, 34); according to HSV-1 serology and frequency of clinical reactivations Table II. Distribution of the receptor/ligand pair KIR2DL2/HLA-C1, according to HSV-1 serology and frequency of clinical reactivations.

<table>
<thead>
<tr>
<th>Category</th>
<th>2DL2/HLA-C1 Frequency [% (n)</th>
<th>p of linear trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatics seronegatives (n = 67)</td>
<td>38.8 (26)</td>
<td>0.005</td>
</tr>
<tr>
<td>Asymptomatics seropositives (n = 71)</td>
<td>43.7 (31)</td>
<td></td>
</tr>
<tr>
<td>Symptomatics, sporadic reactivations</td>
<td>50.8 (32)</td>
<td></td>
</tr>
<tr>
<td>Symptomatics, recurrent reactivations (n = 101)</td>
<td>59.4 (60)</td>
<td></td>
</tr>
</tbody>
</table>

Results confirmed that the presence of HLA-B*18 and a CD16A-158V/V genotype grant protection from HSV-1 reactivation, whereas HLA-C*15, the group of HLA-A alleles encoding the A19 allotype, and the KIR2DL2/C1 receptor/ligand pair (but neither KIR2DL2 nor KIR2DS2 alone) confer susceptibility to suffer herpetic reactivations (Table V). A predictive model on the probability of suffering herpetic lesions was built with the parameters that, in multiple regression, showed a significantly positive or negative association. Such model classified correctly 70.6% of the patients with herpetic symptoms and 58.0% of the asymptomatic donors. An ROC curve, which plots specificity and sensitivity of the model (43), enclosed 68.7% of the maximum possible area (Fig. 5).

**Discussion**

The highly variable clinical course of HSV-1 infection suggests that susceptibility or resistance host genes are involved in its control, as shown for murine CMV and experimental HSV-1 infection (50, 51). However, no major HSV-1 susceptibility locus has been identified in humans, suggesting that polygenic inheritance is responsible for variable susceptibility. In this study, we have analyzed the contribution of gene families that encode key regulators at the interface of adaptive and innate immunity: class I and class II alleles, the CNV of NK cell receptors (KIR and NKG2C), combinations of KIR and their HLA-encoded ligands, and allotypes that modulate the affinity of CD16A and CD32A for IgG. Even though none of these genes arises as a major susceptibility locus, uni- and multivariate analyses indicate that MHC class I alleles, combinations of KIR/ligand pairs, and the CD16A-158V/F dimorphism all modify the risk of suffering clinical HSV-1 infection. In contrast, polymorphisms of HLA class II, NKG2C, and CD32A appear to play no role in susceptibility to HSV-1.

Among HLA class I alleles, B*18 was significantly less common among herpetic patients, an association not observed in other populations. Previous studies indicated that B35 might confer protection against HSV-1 (19, 23, 25, 27); we observed a coincident deviation, but it was only close to significance in uni- and multivariate analysis. In contrast with those HLA-B allotypes, C*15 emerged as a susceptibility factor. This allele had never been studied in HSV-1 infection, because it remained undiscovered until DNA typing methods became available in the mid-1990s (52, 53). Strong association of C*15 with B51 (46) might be related to previous reports on B51 (the common split of the public Ag HLA-B5) behaving as a predisposing factor for symptomatic herpes (17, 18, 20, 26, 27). Finally, multiple regression analysis identified the group of alleles encoding an A19 Ag as possible risk factors; similar results were obtained previously by some (16, 25, 27), but not all (19, 21), groups.

The picture that emerges from comparison of different studies is one in which MHC class I polymorphism appears consistently associated with HSV-1 infection, the predisposing or protective alleles varying in each study. Low reproducibility of results in different populations might bear relation with geographical differences in distribution and haplotypic combinations of HLA.
alleles. Confounding effects can also contribute to conflicting results; among them, small cohorts of <50 patients in many previous studies, control groups composed of general population instead of herpes-resistant donors, and imprecision of serological HLA typing. We have addressed these problems by studying >150 symptomatically infected individuals, and a similarly sized control group comprising only asymptomatic individuals. Furthermore, this is the first study, to our knowledge, performed entirely with DNA-based genotyping methods, of greater precision and reproducibility, and the only techniques currently accepted for HLA-C and class II alleles.

With the exception of C*15 and A*32 (part of the A19 allotype), the HLA class I alleles that appear to modify the outcome of HSV-1 infection do not encode known KIR ligands. Therefore, their divergent roles in the infection should derive from differential functions as Ag-presenting molecules to CD8+ CTls. A peptide prediction tool that takes into account MHC binding, proteasomal C-terminal cleavage, and TAP transport efficacy showed that the possibly protective (HLA-B*35 and B*18) and risk alleles (C*15 and most A19-related alleles) encode molecules that differ in their capacity to present a unique ICP0 9-mer peptide. HSV-1 ICP0, a potential target for CTls (54, 55), is expressed during early infection and latency, and it triggers virus reactivation (47). Therefore, efficacious presentation of ICP0-derived peptides by certain HLA class I molecules could favor CTL control of infective virion production in sensory ganglia (56).

Another aspect in which MHC molecules diverge functionally is in their capacity to overcome the effect of viral immunoevasins. Independence of tapasin binding for peptide loading enables some MHC molecules, including HLA-B35 (57), to migrate more rapidly to the cell surface. Furthermore, although this characteristic is at the expense of binding suboptimal peptides, it overcomes TAP blockade by protein ICP47 during HSV-1 infection (58). Tapasin-independent HLA molecules could therefore be advantageous by presenting HSV-1 Ags early postinfection/reactivation. Unfortunately, tapasin-independence cannot be currently predicted reliably from the primary structure of an HLA allotype, but B18 could share that feature with B35 because it carries a combination of two motifs (aspartate-114 and serine-116) that associate with tapasin-independent (59–62).

Subversion of HLA class I expression in infected cells could facilitate HSV-1 evasion from CTls, but it is also a trigger for cytotoxicity and cytokine secretion by NK cells, which sense it by means of KIR and other MHC receptors. We have previously reported that KIR genes 2DL2 and 2DS2 contribute to the susceptibility to suffer frequent, clinically relevant HSV-1 reactivations (29). Current results show that these genes by themselves increase only modestly the risk of symptomatic herpes. It is mainly the combination of KIR2DL2 with HLA-C alleles encoding its epitope ligand [KIR2DS2 lacks any detectable affinity for HLA (63)] that increases noticeably susceptibility to this disease.

KIR2DL2 is currently considered a 2DL3 allotype of higher affinity (64). Stronger inhibition by KIR2DL2 in the presence of its cognate ligands could explain its association with symptomatic herpes, because it might render NK cells less sensitive to modest decreases in HLA-C expression levels induced by HSV-1 and/or hamper surveillance of viral reactivations by memory CD8 T cells expressing NK receptors. Differences in KIR/ligand affinity are possibly relevant because IFN-γ could attenuate HSV-1 blockade of HLA class I expression on infected epithelial cells (65). Con-
sistent with this model, another high-affinity receptor/ligand pair, 2DL1/C2, further increased the risk conferred by 2DL2/C1. According to this reasoning, association of symptomatic herpes with KIR2DS2 would only reflect its strong linkage disequilibrium with 2DL2. As an anecdotal evidence, KIR genes 2DL2 and 2DS2 segregated separately in three donors of this study: two 2DL2+ 2DS2- donors had HSV-1 symptoms, whereas the single 2DL2- 2DS2+ individual was asymptomatic.

Our study on KIR diversity focused on CNV, but did not take into account possible effects of allelic polymorphism. KIR2DL2 is represented in white populations mostly by two alleles, KIR2DL2*001 and *003 (66). Their products share the three substitutions that make KIR2DL2 a stronger receptor than KIR2DL3 and differ from each other by two amino acid replacements: one in the second Ig-like domain (isoleucine/threonine-200, respectively) and one in the cytoplasmic tail (alanine/threonine-313). The former variation, located far from the ligand-biding region, seems not to modify the receptor affinity (64), but more subtle effects of those polymorphisms on KIR2DL2 function and, hence, on its genetic association with HSV-1 infection, cannot be excluded. Similarly, we have not considered quantitative differences in the affinity of KIR2DL2 for various HLA-C1, and even -C2, ligands (64). Of note in the latter regard, C*15:02, the predominant C*15 allele in Spain (46, 52), encodes a C2 epitope for which KIR2DL2 lacks affinity, and it is recognized with average affinity by KIR2DL1 (64); functional effects of this interaction (e.g., inhibition, education) are yet to be defined. Current data thus provide no clues to understand a possible NK cell-mediated mechanism underlying the observed association of C*15 with HSV-1 infection.

The KIR repertoire of different humans is enormously variable and variegated, not simply because of gene CNV and allelic structural polymorphism; both the receptor density on the cell surface and the proportion of NK cells expressing each KIR vary in each individual. Regulation of the KIR repertoire is incompletely understood, and it is genetically controlled in part by KIR genes and by the HLA context (67). It is possible that certain HLA-C ligands modulate differently the contribution of KIR2DL2 to the KIR repertoire or license to a different extent the effector capacity of NK cells. Further investigation is warranted to determine whether variable usage of KIR2DL2 modulates the influence exerted on defense against HSV-1 by mere presence in the genome of the genes/alleles encoding the receptor and its ligands.

Unidentified ligands for orphan KIR could have escaped our analysis, but no other KIR and their known ligands associated with the clinical course of HSV-1 infection. And neither did CNV of NKG2C, including its homozygous deletion. Confirmation of this result would imply that this lectin-like NK receptor is redundant or plays no major role in defense against HSV-1.

Finally, the higher affinity allotype of CD16A (158V) was identified as a protective factor for symptomatic herpes. Valine-158 possibly enhances efficacy of the humoral response against HSV-1 by inducing a stronger interaction of CD16A with the lower hinge of IgG (37). Importance of this interaction is illustrated by the decoy FcγR evolved by several human viruses, including HSV-1, which, reciprocally, are possibly better counteracted by competing host FcγR allotypes of higher affinity for IgG. Also supporting the importance of CD16A for defense against HSV-1 would be the association of mutations at aa 48 of CD16A with severe infections by herpesviruses, but that association is controversial (68–71). Contrasting with the protective effect of CD16A-158V is the lack of association between clinical herpes and CD32A-131 allotypes of variable affinity. Lack of association might reflect greater importance of effective NK cell-mediated cytotoxicity over phago-


NK cell receptor that recognizes the C1 epitope of MHC class I. *J. Immunol.* 185: 4233–4237.


